Ignite Creation Date:
2024-05-06 @ 2:37 AM
Last Modification Date:
2024-10-26 @ 11:21 AM
Study NCT ID:
NCT02083484
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2018-01-26
First Post:
2014-03-07
Brief Title:
Program for Pembrolizumab MK-3475 in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab MK-3475-030
Sponsor:
Organization:
Merck Sharp Dohme LLC